At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
HB-adMSCsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis
In Brief
A Phase 2 clinical trial evaluating HB-adMSCs for Rheumatoid Arthritis. Completed, enrolled 15 participants across 1 site.
Detailed Summary
Hope Biosciences is conducting a research study of an investigational product called Hope Biosciences autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as a possible treatment for Rheumatoid Arthritis (RA). The study purpose is to evaluate the safety profile of a single IV infusion of HB-adMSCs in subjects with clinical diagnosis of RA.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartSep 2018
First PostedOct 2018
Primary CompletionAug 2020
Study CompletionSep 2020
TodayJul 2026
First PostedOct 2, 2018
Enrollment StartSep 25, 2018
Primary CompletionAug 17, 2020
Study CompletionSep 28, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.8 years ago
Interventions
HB-adMSCsbiological
Hope Biosciences autologous adipose-derived mesenchymal stem cells